– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...
This important work advances our understanding of factors influencing efficacy assessments and biomarker viability for complement-directed gene therapy against age-related macular degeneration. The ...
Greater understanding of the underlying molecular causes of inflammation in CKD may lead to biomarkers that more accurately predict the risk of CVD than those currently available and may reveal new ...
The approval specifies use of the first-in-class agent with ravulizumab (Ultomiris) or eculizumab (Soliris), standard-of-care treatment for PNH. Anywhere from 10-20% of patients with PNH develop ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
PASC, which is otherwise known as long COVID, arises following the recovery from acute infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for ...
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and ...
Copyright: Published by Elsevier Ltd. The complement system is recognised as a protector against blood-borne pathogens and a controller of immune system and tissue ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. The APOE4 variant of apolipoprotein E (apoE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback